Top 20 Biologics - 2007 Sales of Antibodies & Proteins
- Category: FREE Reports
- Published on Thursday, 27 March 2008 18:39
- Hits: 13497
The present FREE Download contains a compilation of the 2007 sales of recombinant biologic products including antibodies, proteins and peptides. The report provides an overview of the 20 best selling biologics (TOP 20 Biologics) and 2007 sales for each class of biologics as well as for selected recombinant and non-recombinant biologics.
TOP 20 Biologics Sales
The sales of the 20 best selling antibodies and proteins in 2007 are listed up, each of them posting more than US$ 1 bln sales in 2007
Therapeutic Proteins Sales
The report compiles 2007 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).
2007 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon and Epogin.
Insulin & Insulin Analogs
2007 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi-Aventis are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.
2007 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer Schering Pharma, CSL Behring, Baxter and Wyeth are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto, Benefix (nonacog).
Interferon alpha and beta
2007 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron from Biogen Idec, Merck Serono and Bayer Schering Pharma as well as for Pegasys, Peg-Intron and Intron A from Roche and Schering-Plough.
Granulocyte Colony-Stimulating Factor (G-CSF)
2007 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim) and Neutrogin (lenograstim) from Amgen, Kirin and Chugai.
Human Growth Hormone (hGH)
2007 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen / Serostim from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono.
Enzyme Replacement Therpay (ERT)
2007 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa) and Naglazyme (galsulfase) from Genzyme, Biomarin, Shire and Dainippon Sumitomo.
Follicle Stimulating Hormone (FSH)
2007 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Schering-Plough.
Therapeutic Antibodies Sales
The report compiles 2006 sales of the major therapeutic antibodies per class: cancer antibodies targeting CD20, Her2, VEGF and EGF-R, anti-TNF antibodies and antiviral antibody.
2007 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab) from Genentech / Roche, Bristol-Myers Squibb, Merch Serono, Imclone and Amgen.
2007 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott and Eisai.
2007 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune (AstraZeneca) are presented.
2007 sales of the recombinant humanized antibody fragment Lucentis targeting VEGF for treatment of age-related macular degeneration from Genentech (Roche) and Novartis are presented.
Selected Other Biologics
2007 sales of selected biologics (antibodies, proteins and peptides) are presented including the PTH products Forteo (teriparatide) and Preotact / Preos from Eli Lilly and NPS Pharmaceuticals / Nycomed, the GLP-1 analog Byetta (exenatide) from Eli Lilly and Amylin Pharmaceuticals, and the human growth factor rhBMP2 Inductos from Wyeth as well as botulinum toxin type A, glatiramer acetate (Copaxone), Xigris, Raptiva, Xolair, ReoPro, Integrilin, Tysabri, Actemra, Orencia
Table of Content
- Top 20 Blockbusters
- Top Selling Classes of Biological Products
- Cancer Antibodies
- Anti-TNF Biologics
- Insulin Products
- Rec. Coagulation Factors
- Interferon beta
- human Growth Hormone
- Interferon alfa
- Enzyme Replacement
- Ophthalmology Antibody
- Antiviral Antibody
- Follicle Stimulating Hormones
- Selected Recombinant Biologics
- Selected Non-Recombinant Biologics